SCHEMBL29465653

SCHEMBL29465653

Fc1ccc(-c2nc(-c3ccc4ccccc4c3F)[nH]c2-c2ccncc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 1.00
CSNK1D P48730 5/20 1.00
CSNK1E P49674 4/20 1.00
MAPK13 O15264 9/20 0.78
GCGR P47871 9/20 0.78
MAPK12 P53778 9/20 0.78
MAPK11 Q15759 9/20 0.78
ALOX5 P09917 5/20 0.65
PRKD3 O94806 1/20 0.64
MAP4K4 O95819 1/20 0.64
FRK P42685 1/20 0.64
MAPK9 P45984 1/20 0.64
CSNK1A1 P48729 1/20 0.64
GSK3B P49841 1/20 0.64
PTK6 Q13882 1/20 0.64
PRKD2 Q9BZL6 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17002321 1.00 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL19952769 0.88 MAPK14 (0.79) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL2650029 0.88 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL26677067 0.85 MAPK14 (0.74) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL22778283 0.84 MAPK14 (0.72) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL30365518 0.83 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL17002323 0.83 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL17002312 0.82 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL30365700 0.82 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL30197605 0.81 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115413669-B Kinase inhibitor and application of composition thereof in improving bacterial wilt resistance of plants 湖南大学 2024-03-15 CN claimed
CN-115413669-A Application of kinase inhibitor and combined agent thereof in improving bacterial wilt resistance of plants 湖南大学 2022-12-02 CN claimed
US-12295955-B2 TTP phosphorylation for the identification of personalized medicines KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2025-05-13 US disclosed
US-20240390406-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2024-11-28 US disclosed
EP-4467978-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS King Faisal Specialist Hospital & Research Centre (SA) 2024-11-27 EP disclosed
CN-115413669-B Kinase inhibitor and application of composition thereof in improving bacterial wilt resistance of plants 湖南大学 2024-03-15 CN disclosed
CN-115413669-B Kinase inhibitor and application of composition thereof in improving bacterial wilt resistance of plants 湖南大学 2024-03-15 CN disclosed
US-20230310437-A1 TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2023-10-05 US disclosed
US-11648251-B2 TTP phosphorylation as a biomarker in targeted therapy KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2023-05-16 US disclosed
CN-112142745-B Casein kinase 1 epsilon inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2023-03-21 CN disclosed
CN-115413669-A Application of kinase inhibitor and combined agent thereof in improving bacterial wilt resistance of plants 湖南大学 2022-12-02 CN disclosed
CN-115413669-A Application of kinase inhibitor and combined agent thereof in improving bacterial wilt resistance of plants 湖南大学 2022-12-02 CN disclosed
US-20220251092-A1 CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2022-08-11 US disclosed
EP-3964512-A1 CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2022-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251092-A1 CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF CSNK1E, CSNK1A1, CSNK1G1 MAPK14 874/4885CSNK1D 6/4885CSNK1E 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.